BioCatalystWatch
CTNMWorkspace / CTNM / OverviewCompany library
Contineum Therapeutics, Inc. logo

Contineum Therapeutics, Inc.

Contineum Therapeutics, Inc. (CTNM)

Website

Price
Market cap
Next catalystEstimated PROPEL-IPF completion in June 2028, based on enrollment to date at clinical sitesPIPE-791 — PROPEL-IPF · Study completionSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

PIPE-791

LPA1 receptor (LPAR1)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

PIPE-791

LPA1 receptor (LPAR1)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

PIPE-791

LPA1 receptor (LPAR1)

PreINDP1P2P3FilingApproved

Partner / License out

M1 receptor (M1R)

PreINDP1P2P3FilingApproved

History / paused

PIPE-791

LPA1 receptor (LPAR1)

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

CTNM PR & News

PR & News

CTNM SEC archive